e-learning
resources
Munich 2006
Wednesday 06.09.2006
Interstial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report
P. Pohunek, J. Nemeckova, T. Svobodova, I. Poncakova, J. Vavrinec (Prague, Ceske Budejovice, Czech Republic)
Source:
Annual Congress 2006 - Interstial lung diseases
Session:
Interstial lung diseases
Session type:
Poster Discussion
Number:
4775
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Pohunek, J. Nemeckova, T. Svobodova, I. Poncakova, J. Vavrinec (Prague, Ceske Budejovice, Czech Republic). Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report. Eur Respir J 2006; 28: Suppl. 50, 4775
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Standard therapy for sarcoidosis
Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis
Year: 2005
Severe asthma biologic treatment in the era of COVID-19 – case series
Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Year: 2021
Therapeutic options for sarcoidosis: old and new
Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005
Year: 2005
Efficacy of traditional and combined therapy in patients with sarcoidosis
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003
Super-response to dupilumab therapy in a patient with severe asthma and ABPA – a case report
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Reasons for not receiving interventional therapy in patients with severe emphysema
Source: International Congress 2018 – Endoscopic lung volume reduction
Year: 2018
Treatment out-come in acquired drug resistance tuberculous patients receiving tailored regimen based on sensitivity report
Source: Annual Congress 2008 - Outcomes of tuberculosis treatment
Year: 2008
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy?
Source: Eur Respir J 2001; 18: Suppl. 33, 24s
Year: 2001
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Glucocorticosteroid treatment in sarcoidosis: comparison of regimens
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003
Our clinical experience in surgical therapy of patients with bronchiectasis
Source: Eur Respir J 2002; 20: Suppl. 38, 344s
Year: 2002
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Sarcoidosis caused by interferon therapy: case report
Source: Eur Respir J 2003; 22: Suppl. 45, 233s
Year: 2003
A retrospective analysis of methotrexate therapy as a steroid sparing agent within a UK severe asthma clinic
Source: Annual Congress 2012 - Different ways to phenotype asthma
Year: 2012
Long-term treatment with infliximab in patients with sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Corticosteroid treatment in sarcoidosis
Source: Eur Respir J 2006; 28: 627-636
Year: 2006
Follow-up of the patients with newly diagnosed sarcoidosis treated with oral corticosteroids. Features associated with chronic sarcoidosis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008
The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002
Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis
Source: Eur Respir J 2014; 43: 602-609
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept